Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

Darren K McGuire, Jeffrey R. Winterfield, Jason A. Rytlewski, Ele Ferrannini

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin- aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

Original languageEnglish (US)
Pages (from-to)59-66
Number of pages8
JournalDiabetes and Vascular Disease Research
Volume5
Issue number1
DOIs
StatePublished - Mar 2008

Fingerprint

Renin-Angiotensin System
Diabetes Mellitus
Cardiovascular Diseases
Primary Prevention
Type 2 Diabetes Mellitus
Public Health
Clinical Trials
Glucose
Pharmaceutical Preparations

Keywords

  • Angiotensin receptor blocker (ARB)
  • Angiotensin-converting enzyme (ACE) inhibitor
  • Diabetes
  • Prevention
  • Renin-angiotensin-aldosterone system

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. / McGuire, Darren K; Winterfield, Jeffrey R.; Rytlewski, Jason A.; Ferrannini, Ele.

In: Diabetes and Vascular Disease Research, Vol. 5, No. 1, 03.2008, p. 59-66.

Research output: Contribution to journalArticle

McGuire, Darren K ; Winterfield, Jeffrey R. ; Rytlewski, Jason A. ; Ferrannini, Ele. / Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. In: Diabetes and Vascular Disease Research. 2008 ; Vol. 5, No. 1. pp. 59-66.
@article{d12fb7d30047411f9d41a5f6c835af9e,
title = "Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus",
abstract = "Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin- aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.",
keywords = "Angiotensin receptor blocker (ARB), Angiotensin-converting enzyme (ACE) inhibitor, Diabetes, Prevention, Renin-angiotensin-aldosterone system",
author = "McGuire, {Darren K} and Winterfield, {Jeffrey R.} and Rytlewski, {Jason A.} and Ele Ferrannini",
year = "2008",
month = "3",
doi = "10.3132/dvdr.2008.011",
language = "English (US)",
volume = "5",
pages = "59--66",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus

AU - McGuire, Darren K

AU - Winterfield, Jeffrey R.

AU - Rytlewski, Jason A.

AU - Ferrannini, Ele

PY - 2008/3

Y1 - 2008/3

N2 - Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin- aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

AB - Type 2 diabetes mellitus (DM) is increasing around the world, and the public health impact of DM, driven largely by cardiovascular disease complications, underpins the importance of continued efforts toward primary prevention of DM. Only a few interventions have been shown to prevent DM, with none of them yet proven to improve cardiovascular risk commensurately. Accumulating evidence suggest that drugs that block the renin-angiotensin- aldosterone system (RAAS), many of which have proven cardiovascular disease (CVD) benefit, also have favourable effects on parameters of glucose metabolism and incident diabetes. Here we review the evidence accumulated to date from animal studies, clinical mechanistic studies and clinical trials regarding the effect of RAAS inhibition and incident DM.

KW - Angiotensin receptor blocker (ARB)

KW - Angiotensin-converting enzyme (ACE) inhibitor

KW - Diabetes

KW - Prevention

KW - Renin-angiotensin-aldosterone system

UR - http://www.scopus.com/inward/record.url?scp=41949101054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949101054&partnerID=8YFLogxK

U2 - 10.3132/dvdr.2008.011

DO - 10.3132/dvdr.2008.011

M3 - Article

C2 - 18398815

AN - SCOPUS:41949101054

VL - 5

SP - 59

EP - 66

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 1

ER -